Results 51 to 60 of about 5,518 (165)

Novel chemotype NLRP3 inhibitors that target the CRID3-binding pocket with high potency

Life Science Alliance
The NLRP3 inflammasome drives various diseases. Here, we describe novel potent and selective NLRP3-targeted inhibitors to bolster pharmacological studies and development of NLRP3-targeted therapies.
Lieselotte Vande Walle, Madhukar Said, Oonagh Paerewijck, Arinna Bertoni, Marco Gattorno, Bruno Linclau, Mohamed Lamkanfi   +6 more
doaj   +1 more source

Evaluating associations between the benefits and risks of drug therapy in type 2 diabetes: a joint modeling approach

Clinical Epidemiology, 2018
John M Dennis,1 Beverley M Shields,2 Angus G Jones,2 Ewan R Pearson,3 Andrew T Hattersley,2 William E Henley1 On behalf of the MASTERMIND consortium 1Health Statistics Group, University of Exeter Medical School, Exeter, UK; 2National Institute for ...
Dennis JM, Shields BM, Jones AG, Pearson ER, Hattersley AT, Henley WE   +5 more
doaj  

The Development of Sulfonylurea Compounds

Hans Journal of Medicinal Chemistry, 2014
openaire   +1 more source

Sulfonylurea Bioisosteres of Sulfonic Acid in JFD 00458-Based ST6GAL1 Inhibitors Enhance Membrane Permeability. [PDF]

ChemMedChem
Koraj N, Dangudubiyyam S, Betances-Mora AM, Faganeli E, Harduin-Lepers A, Angulo J, Nguyen TK, Bort-Griñó M, Hurtado-Guerrero R, Anderluh M.   +9 more
europepmc   +1 more source

Plasmid-Mediated AmpC Detection in <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i>: In Vitro Prevalence and In Silico Inhibitor Design. [PDF]

Can J Infect Dis Med Microbiol
Sarfraz M, Amin A, Naveed M, Ahmed M, Hasnain S, Naz S, Khurshid M, Cheema MT, Ikram S, Ahmad A.   +9 more
europepmc   +1 more source

Synthesis, Herbicidal Activity Evaluation, and Molecular Docking of Novel Acylthioureas as AHAS Inhibitors. [PDF]

Molecules
Jiang B, Chen X, He X, Chai Y, Wang Y, Li R.   +5 more
europepmc   +1 more source

Disentangling Sex Differences in Sulfonylurea Drug Response With Genome-Wide Association Studies in Individuals With Type 2 Diabetes. [PDF]

Clin Pharmacol Ther
Breeyear JH, House JS, Kvale M, Nam S, Akhtari FS, Shah HS, Hedderson MM, Giacomini KM, Mychaleckyj JC, Doria A, Wagner MJ, Li JH, Yee SW, Buse JB, Woychik RP, Rotroff DM, Motsinger-Reif AA.   +16 more
europepmc   +1 more source

Deconstructing the Master Switch: Advances in Direct NLRP3 Inhibition. [PDF]

Pharmaceuticals (Basel)
Xu Y, Murphy S.
europepmc   +1 more source

Risk of Severe Hypoglycemia Associated With Concomitant Use of Sulfonylureas and Amiodarone. [PDF]

Diabetes Obes Metab
Bea S, Lee H, Cho YM, Choi YJ, Shin JY, Bykov K.   +5 more
europepmc   +1 more source

Nanoceria as an Acid-Base Catalyst for Interfacial Hydrolysis of Sulfonylureas: A Combined 31P MAS NMR and DFT Study. [PDF]

Inorg Chem
Čundrle J, Št'astný M, Dušková T, Bavol D, Popelková D, Ederer J, Rifat NJ, Xu Y, Henych J.   +8 more
europepmc   +1 more source